Impact of New WHO HIV Treatment Guidelines
Author Information
Author(s): Jan A. C. Hontelez, Sake J. de Vlas, Frank Tanser, Roel Bakker, Till Bärnighausen, Marie-Louise Newell, Rob Baltussen, Mark N. Lurie
Primary Institution: Erasmus MC, University Medical Centre Rotterdam
Hypothesis
What is the impact of fully adopting the new WHO guidelines on HIV epidemic dynamics and associated costs in South Africa?
Conclusion
The study supports the WHO recommendation of starting ART at ≤350 cells/µl for all HIV-infected patients, leading to net savings and increased life-years saved.
Supporting Evidence
- Starting ART at ≤350 cells/µl will lead to a modest increase in program costs but significantly more patients on ART.
- Cumulative net cost-savings are expected to start around 2026.
- The new guidelines will yield about 160,000 life-years saved by 2040.
- Initial costs are higher due to more patients being eligible for treatment, but long-term costs may decrease.
- The model accurately reflects the demographic and epidemiological situation of the Hlabisa subdistrict.
Takeaway
The new WHO guidelines suggest starting HIV treatment earlier, which will help more people and save money in the long run.
Methodology
The study used a microsimulation model to predict HIV epidemic dynamics and costs under different treatment initiation thresholds.
Limitations
The findings may be overly optimistic for South Africa as a whole due to higher dropout rates and lower health-seeking behavior in the general population.
Participant Demographics
The study focuses on the Hlabisa subdistrict in KwaZulu-Natal, South Africa, which has a high HIV prevalence.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website